Japan Single-Use Bioprocessing Products Market 2024–2031: Market Size, Company Trends and Analysis Report Released

Japan's single-use bioprocessing products market was valued at XX million US dollars in 2023 and is projected to expand to XX million US dollars by 2031, with a compound annual growth rate (CAGR) of XX% expected from 2024 to 2031. The report analyzes market size, share, growth rates and demand trends by product type, application, end user and region.

Growth drivers include the expansion of domestic biopharmaceutical production in Japan and increased investment in a range of modalities, including antibodies, vaccines, cell therapies, gene therapies and mRNA. Newly established and expanded manufacturing facilities serving these areas are expected to drive demand for single-use equipment.

As an example, AGC is constructing a new manufacturing facility at the Yokohama Technical Center. Scheduled to begin operations in 2026, the facility is intended to provide services for mammalian cell-derived protein therapeutics, cell therapies and mRNA products, from the preclinical stage through commercial manufacturing. The increase in this type of capital investment is expected to support market expansion. Domestic competition is also intensifying, with GVS Japan K.K. launching single-use products in April 2024.

Challenges include the environmental impact associated with increasing plastic waste and issues related to waste disposal. Tighter environmental regulations and growing public pressure to reduce plastic use may affect market adoption.

In the competitive landscape, Thermo Fisher Scientific, SATAKE MultiMix Corporation, Sartorius, Cytiva, Asahi Kasei, Merck KGaA, Eppendorf, Boehringer Ingelheim International, ZACROS and REPROCELL are among the leading companies. The ability to supply comprehensive platforms of related equipment and materials, including single-use bioreactors (SUBs), is a key competitive factor.